+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Transdermal Drug Delivery System Market by Type (Transdermal Patches, Transdermal Semisolids), Application (Cardiovascular Diseases, Central Nervous System Disorders, Hormonal Applications), End User - Forecast 2024-2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 4896809
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Transdermal Drug Delivery System Market size was estimated at USD 6.98 billion in 2023, USD 7.32 billion in 2024, and is expected to grow at a CAGR of 5.06% to reach USD 9.87 billion by 2030 .

Transdermal drug delivery comprises the production, distribution, and application of therapeutic methods that facilitate the controlled release of medications through the skin. This innovative approach offers numerous advantages over conventional oral or intravenous drug administration, such as increased patient compliance, reduced side effects, and improved pharmacokinetic profiles. The TDDS encompasses various technologies, including passive diffusion systems, iontophoresis, microneedles, and ultrasound-mediated techniques. The increase in the aging population and the growing prevalence of chronic diseases necessitate more practical and convenient drug delivery methods. Furthermore, advancements in nanotechnology and materials science have enabled the development of sophisticated transdermal patches that offer superior drug permeation across biological membranes without causing irritation or discomfort to patients. However, high development costs associated with producing complex transdermal systems and incidences of product recalls may adversely impact their use in the healthcare sector. Besides, advanced drug delivery vehicles demonstrate promising potential to improve the bioavailability and solubility of water-soluble drugs, enabling more effective transdermal drug delivery strategies.

Regional Insights

The transdermal drug delivery market is evolving in the Americas due to its well-established healthcare infrastructure and research & development activities. Regulatory bodies in the Americas ensure adherence to standard guidelines while approving new products, resulting in the development of innovative transdermal technologies. The APAC region has a growing demand for advanced healthcare technologies due to increasing disposable incomes, population aging, and the need for efficient treatments. The transdermal drug delivery system market is growing in the EMEA region due to the presence of pharmaceutical industries, increased healthcare spending, and the rapid expansion of its manufacturing capabilities for transdermal systems. Moreover, the increasing adoption of personalized medicine and targeted therapies presents further prospects for TDDS systems tailored to specific patient populations or disease conditions.

Type: Ongoing regulatory and government approvals for transdermal patches

Transdermal patches are adhesive-coated, medicated patches designed to deliver a specific drug dosage through the skin and into the bloodstream over an extended period. They offer several advantages over conventional oral and parenteral drug delivery systems, such as improved patient compliance, reduced side effects, and controlled release of active ingredients. Drug-in-adhesive patches, matrix patches, microneedle patches, and reservoir membrane patches are available and are used according to medical requirements. The preference for transdermal patches is mainly due to their non-invasive nature and ease of application. They are suitable for patients experiencing difficulties swallowing pills or for those with gastrointestinal issues that may affect the absorption of medications. Transdermal semisolids include gels, creams, and ointments formulated with drugs that are absorbed through the skin into the systemic circulation. These dosage forms offer benefits such as easy application and removal, localized treatment without systemic side effects for certain conditions, and flexibility in formulation. Transdermal patches provide more consistent drug release than semisolids since they possess a controlled-release mechanism. Additionally, patches show better adhesion to the skin surface than semisolids, which may require frequent reapplication of the gels or creams.

Application: Need for minimally invasive drug delivery systems for management of cardiovascular diseases

Transdermal drug delivery systems are preferred in treating cardiovascular diseases such as angina pectoris or hypertension due to their ability to maintain constant plasma medication levels with fewer side effects. Nitroglycerin patches have been extensively used for angina patients, offering continuous relief without the need for frequent oral administration. TDDS displays an enhanced potential in managing central nervous system disorders, including Parkinson's disease and Alzheimer's disease, by maintaining steady concentrations of drugs. The continuous delivery minimizes fluctuations observed with oral medications, which can lead to breakthrough symptoms or side effects. Hormonal applications of TDDS include contraception, hormone replacement therapy (HRT), and testosterone supplementation. Transdermal patches offer advantages in maintaining steady hormone levels, reducing side effects, and improving patient compliance. Transdermal systems have gained popularity in managing chronic pain conditions, including musculoskeletal disorders or cancer-related pain, due to their ability to deliver analgesics directly to the affected area for long durations while minimizing systemic side effects. Transdermal estrogen therapy is essential for hormone replacement therapy for menopausal symptoms or osteoporosis management in postmenopausal women.

End-User: Preference for self-administration of drugs leading to demand for drug delivery systems that can be implemented in home care settings

Transdermal drug delivery systems are being utilized within particular innovative clinics for skin care and are implemented into the more effective health care system. With the growing understanding of drug delivery and the continued efforts of medical doctors, engineers, and scientists to advance this technology, an ultrasound-based transdermal delivery platform is expected to be a step closer to clinical applications. Clinical impact relies on a transdermal delivery system that administers drugs safely and effectively, is low-cost and easy to use, and is designed for self-administration at home. Transdermal drug delivery has recently gained popularity due to its unique and advantageous properties, which provide prospective benefits over conventional routes of drug administration in the therapy of numerous illnesses in hospital settings. Hospitals and clinics serve several patients in rural regions, particularly senior populations. These pharmacists help patients at a higher risk of medication interactions or illness complications due to a lack of control over their condition.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Transdermal Drug Delivery System Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Transdermal Drug Delivery System Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Transdermal Drug Delivery System Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Transdermal Drug Delivery System Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Transdermal Drug Delivery System Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Transdermal Drug Delivery System Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Transdermal Drug Delivery System Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Transdermal Drug Delivery System Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Transdermal Drug Delivery System Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Transdermal Drug Delivery System Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Transdermal Drug Delivery System Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Transdermal Drug Delivery System Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Transdermal Drug Delivery System Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease

Luye Pharma Group announced the approval of its Rivastigmine Twice Weekly Transdermal Patch by China's National Medical Products Administration (NMPA) for the treatment of mild to moderate Alzheimer's disease. This breakthrough originates from Luye's own European-based transdermal patch platform and is now set to serve the Chinese market, bolstered by the collaborative effort with Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci).

Satio Wins USD 3.5 Million Contract To Develop At-Home Transdermal Drug Delivery Device

Satio's latest advancement in drug delivery technology, bolstered by a USD 3.5 million SBIR contract from the NIH's ARPA-H. The contract is aimed to fuel the development of SatioRx, a novel, compact, and cost-effective transdermal drug delivery device. This innovation stands apart with its disposable microneedle components that promise precise and painless medication dosing directly into the bloodstream, revolutionizing the way liquid drugs are administered transdermally.

LTS Completes Its Entry Into Large Molecule Drug Delivery With The Acquisition Of The Sorrel Wearable Injection Device Business

LTS has expanded its large molecule drug delivery portfolio by acquiring the Sorrel Wearable Injection Device Business. This acquisition includes exclusive intellectual property, engineering expertise, and commercialization capabilities related to the Sorrel device. With LTS's Transdermal Drug Delivery System, patients suffering from chronic diseases now have access to a non-invasive method of self-administering medications on a continuous basis.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Transdermal Drug Delivery System Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Transdermal Drug Delivery System Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AdhexPharma, SAS, Bayer AG, Biotts Inc., Boehringer Ingelheim International GmbH, DuPont de Nemours, Inc., Gensco Pharma, Hisamitsu Pharmaceutical Co., Inc., IBSA Farmaceutici Italia Srl, IntelGenx Corp., Johnson & Johnson Services, Inc., Kindeva Drug Delivery L.P., Lavipharm S.A., Lead Chemical Co., Ltd., Luye Life Sciences Group, Medherant Limited, Nitto Denko Corporation, Novartis International AG, Nutriband Inc., Purdue Pharma L.P., Sorrento Therapeutics, Inc., Sparsha Pharma International Pvt. Ltd., Starton Therapeutics, Toa Eiyo Ltd., Toyo Ink SC Holdings Co., Ltd., Transdermal Therapeutics, Inc., UCB S.A., Viatris Inc., Zhongshan Senwell Bio Technology Co., Ltd., and Zynerba Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Transdermal Drug Delivery System Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Transdermal Patches
      • Drug-In-Adhesive Patches
      • Matrix Patches
      • Microneedle Patches
      • Reservoir Membrane Patches
    • Transdermal Semisolids
      • Gels
      • Ointments
      • Sprays
  • Application
    • Cardiovascular Diseases
    • Central Nervous System Disorders
    • Hormonal Applications
    • Pain Management
    • Transdermal Estrogen Therapy
  • End User
    • Home Care Settings
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Transdermal Drug Delivery System Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases and the need for effective drug delivery
5.1.1.2. Surging adoption of third-generation transdermal drug delivery system
5.1.2. Restraints
5.1.2.1. Concerns associated with irritation or skin sensitivity over patch usage
5.1.3. Opportunities
5.1.3.1. Ongoing research & development in transdermal drug delivery system
5.1.3.2. Inorganic growth strategies between pharmaceutical companies and TDDS vendors
5.1.4. Challenges
5.1.4.1. Probable risk of drug failure through transdermal systems and product recalls
5.2. Market Segmentation Analysis
5.2.1. Type: Ongoing regulatory and government approvals for transdermal patches
5.2.2. Application: Need for minimally invasive drug delivery systems for management of cardiovascular diseases
5.2.3. End-User: Preference for self-administration of drugs leading to demand for drug delivery systems that can be implemented in home care settings
5.3. Market Trend Analysis
5.3.1. Potential power of market players and surge in regulatory approvals in the American region
5.3.2. Surging healthcare spendings and inclusion of overseas players in the APAC region
5.3.3. Persistent research activities and the growing burden of chronic disease in the EMEA region.
5.3.4. Revolutionizing transdermal drug delivery with electronic skin
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
6. Transdermal Drug Delivery System Market, by Type
6.1. Introduction
6.2. Transdermal Patches
6.3. Transdermal Semisolids
7. Transdermal Drug Delivery System Market, by Application
7.1. Introduction
7.2. Cardiovascular Diseases
7.3. Central Nervous System Disorders
7.4. Hormonal Applications
7.5. Pain Management
7.6. Transdermal Estrogen Therapy
8. Transdermal Drug Delivery System Market, by End User
8.1. Introduction
8.2. Home Care Settings
8.3. Hospitals & Clinics
9. Americas Transdermal Drug Delivery System Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Transdermal Drug Delivery System Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Transdermal Drug Delivery System Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease
12.3.2. Satio Wins USD 3.5 Million Contract To Develop At-Home Transdermal Drug Delivery Device
12.3.3. LTS Completes Its Entry Into Large Molecule Drug Delivery With The Acquisition Of The Sorrel Wearable Injection Device Business
12.3.4. DifGen Pharmaceuticals Acquires Aveva Drug Delivery Services Inc.
12.3.5. Zydus Lifesciences gets Final Approval from the U.S. FDA to Market Estradiol Transdermal System
12.3.6. Kindeva Merges with Meridian to Create Global CDMO Specializing in Drug-Device Combinations
12.3.7. LTS Lohmann Leads Investment in Needle-Free Delivery Specialist
12.3.8. Love Pharma Moves To Buy Transdermal Opioid-Use Disorder Player
12.3.9. Corium Launches ADLARITY (donepezil transdermal system) for Patients with Alzheimer's Dementia
12.3.10. Lowenstein Represents Pharma Tech LTS Lohmann Therapy Systems, Corp. in Acquisition of Tapemark Inc.
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET RESEARCH PROCESS
FIGURE 2. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET DYNAMICS
FIGURE 7. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 12. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY MATRIX PATCHES, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY MATRIX PATCHES, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLE PATCHES, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLE PATCHES, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY RESERVOIR MEMBRANE PATCHES, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY RESERVOIR MEMBRANE PATCHES, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY SPRAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY SPRAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HORMONAL APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HORMONAL APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL ESTROGEN THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL ESTROGEN THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 50. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 61. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 62. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 63. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 64. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 65. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 66. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 67. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 68. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 71. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 72. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 73. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 74. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 75. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 76. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 77. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 78. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 79. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 80. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 81. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 82. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 83. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 84. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 85. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 86. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 87. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 88. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 89. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 90. CANADA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 91. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 92. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 93. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 94. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 95. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 96. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 97. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 98. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 99. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 100. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 101. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 102. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 103. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 104. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 105. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 106. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 107. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 108. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 109. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 110. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 111. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 112. UNITED STATES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 114. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 116. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 118. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 120. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 124. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 125. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 126. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 127. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 128. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 129. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 130. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 131. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 132. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 133. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 134. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 135. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 136. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 137. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 138. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 139. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 140. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 141. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 142. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 143. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 144. CHINA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 145. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 146. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 147. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 148. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 149. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 150. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 151. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 152. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 153. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 154. INDIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 155. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 156. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 157. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 158. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 159. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 160. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 161. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 162. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 163. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 164. INDONESIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 165. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 166. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 167. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 168. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 169. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 170. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 171. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 172. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 173. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 174. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 175. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 176. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 177. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 178. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 179. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 180. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 181. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 182. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 183. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 184. MALAYSIA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 185. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 186. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 187. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 188. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 189. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 190. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 191. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 192. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 193. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 194. PHILIPPINES TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 195. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 196. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 197. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 198. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 199. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 200. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 201. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 202. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 203. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 204. SINGAPORE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 205. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 206. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 207. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 208. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 209. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 210. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 211. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 212. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 213. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 214. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 215. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 216. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 217. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 218. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 219. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 220. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 221. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 222. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 223. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 224. TAIWAN TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 225. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 226. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 227. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 228. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 229. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 230. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 231. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 232. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 233. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 234. THAILAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 235. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 236. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 237. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 238. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 239. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 240. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 241. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 242. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 243. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 244. VIETNAM TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 257. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 258. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 259. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 260. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 261. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 262. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 263. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 264. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 265. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 266. DENMARK TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 267. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 268. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 269. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 270. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 271. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 272. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 273. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 274. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 275. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 276. EGYPT TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 277. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 278. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 279. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 280. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 281. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 282. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 283. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 284. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 285. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 286. FINLAND TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 287. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 288. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 289. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 290. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 291. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2018-2023 (USD MILLION)
TABLE 292. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL SEMISOLIDS, 2024-2030 (USD MILLION)
TABLE 293. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 294. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 295. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 296. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 297. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 298. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 299. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2023 (USD MILLION)
TABLE 300. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL PATCHES, 2024-2030 (USD MILLION)
TABLE 301. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEM MARKET SIZE, BY TRANSDERMAL

Companies Mentioned

  • 3M Company
  • AdhexPharma, SAS
  • Bayer AG
  • Biotts Inc.
  • Boehringer Ingelheim International GmbH
  • DuPont de Nemours, Inc.
  • Gensco Pharma
  • Hisamitsu Pharmaceutical Co., Inc.
  • IBSA Farmaceutici Italia Srl
  • IntelGenx Corp.
  • Johnson & Johnson Services, Inc.
  • Kindeva Drug Delivery L.P.
  • Lavipharm S.A.
  • Lead Chemical Co., Ltd.
  • Luye Life Sciences Group
  • Medherant Limited
  • Nitto Denko Corporation
  • Novartis International AG
  • Nutriband Inc.
  • Purdue Pharma L.P.
  • Sorrento Therapeutics, Inc.
  • Sparsha Pharma International Pvt. Ltd.
  • Starton Therapeutics
  • Toa Eiyo Ltd.
  • Toyo Ink SC Holdings Co., Ltd.
  • Transdermal Therapeutics, Inc.
  • UCB S.A.
  • Viatris Inc.
  • Zhongshan Senwell Bio Technology Co., Ltd.
  • Zynerba Pharmaceuticals, Inc.

Methodology

Loading
LOADING...

Table Information